DKG
KREBSGESELLSCHAFT

Annual Report 2017
of the certified Oncology Centres



DKG
KREBSGESELLSCHAFT

2017

Annual Report of the certified Oncology Centres

RESPONSIBLE INTERDISCIPLINARITY
Representatives on the Certification Committee Oncology Centres

Arbeitsgemeinschaft Bildgebung in der Onkologie (ABO); Arbeitsgemeinschaft Deutscher Tumorzentren (ADT); Arbeitsgemeinschaft Dermatologische Onkologie (ADO); Arbeitsgemeinschaft Gynäkologische Onkologie (AGO); Arbeitsgemeinschaft Hals-Nasen-Ohren-Heilkunde, Mund-Kiefer-Gesichtschirurgische Onkologie (AHMO); Arbeitsgemeinschaft Internistische Onkologie (AIO); Arbeitsgemeinschaft Onkologische Pathologie (AOP); Arbeitsgemeinschaft Palliative Medizin (APM); Arbeitsgemeinschaft für Onkologische Pharmazie (OPH); Arbeitsgemeinschaft Onkologische Thoraxchirurgie (AOT); Arbeitsgemeinschaft Pädiatrische Onkologie (APO); Arbeitsgemeinschaft Urologische Onkologie (AUO); Arbeitsgemeinschaft Prävention und integrative Onkologie (PRIO); Arbeitsgemeinschaft für Psychoonkologie (PSO); Arbeitsgemeinschaft Radiologische Onkologie (ARO); Arbeitsgemeinschaft Supportive Massnahmen in der Onkologie, Rehabilitation und Sozialmedizin (ASORS); Berufsverband der niedergelassenen Hämatologen und Onkologen (BNHO); Bundesverband Deutscher Pathologen e.V.Chirurgische Arbeitsgemeinschaft Onkologie (CAO); Chirurgische Arbeitsgemeinschaft Onkologie der Deutschen Gesellschaft für Viszeralchirurgie (CAO-V); Deutsche Dermatologische Gesellschaft (DDG); Deutsche Gesellschaft der Plastischen, Rekonstruktiven und Ästhetischen Chirurgen (DGPRÄC); Deutsche Gesellschaft für Chirurgie (DGCh); Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG); Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO); Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-ChirurgieDeutsche Gesellschaft für Mund-Kiefer-Gesichtschirurgie (DGMKG); Deutsche Gesellschaft für Neurologie (DGN); Deutsche Gesellschaft für Nuklearmedizin (DGN); Deutsche Gesellschaft für Orthopädie und Orthopädische Chirurgie (DGOOC); Deutsche Gesellschaft für Palliativmedizin (DGP); Deutsche Gesellschaft für Pathologie (DGP); Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin (DGP); Deutsche Gesellschaft für Radioonkologie (DEGRO); Deutsche Gesellschaft für Studium des Schmerzes (DGSS); Deutsche Gesellschaft für Thoraxchirurgie (DGT); Deutsche Gesellschaft für Urologie (DGU); Deutsche Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS); Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV); Deutsche Krebsgesellschaft (DKG); Deutsche Krebshilfe (DKH); Deutsche Röntgengesellschaft (DRG); Deutsche Vereinigung für Sozialarbeit im Gesundheitswesen (DVSG); Haus der Krebsselbsthilfe - Bundesverband e.V. Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH); Konferenz onkologischer Kranken- und Kinderkrankenpflege (KOK); Neuroonkologische Arbeitsgemeinschaft (NOA); Pneumologisch-Onkologische Arbeitsgemeinschaft (POA); Sprecher des Netzwerkes der Onkologischen Spitzenzentren (CCC); Sprecher der Kommissionen der Organkrebszentren und Organmodule.



113 locations
Status as of 01.03.2017

1. Presentation of the Certification System

2. Data - DKG Certification System

3. Data - Oncology Centres

4. Media / Webportals

1. PRESENTATION OF THE CERTIFICATION SYSTEM

The objective and mandate of the DKG certification system is the establishment of a certified network in which patients are treated in a comprehensive, interdisciplinary and multi-professional manner on the basis of evidence-based guidelines. The quality of treatment within the network is recorded, evaluated and used for ongoing quality improvements as part of the audit processes.

1.1 Organigram - Certification System

NationaleCancer Certification Programme (German Cancer Society and German Cancer Aid)

Certification Committee Oncology Centre

Chairperson: Prof. Graeven (DKG)
Deputy chairperson: Prof. von Kalle (DKH) / Prof. Lang (DKG)

Specialist societies / Professional associations / Working groups

Comprehensive Cancer Centres

Certification Committees

Breast	**Gyn**	**Visceral Oncology Centre** Colon/rectum, liver, oesophagus, pancreas, stomach)	**Skin**	**Lung**
Chairperson: Prof. Blohmer / Prof. Scharl	Chairperson: Prof. Beckmann	Chairperson: Prof. Seufferlein Deputy chairperson: Prof. Post	Chairperson: Prof. Grabbe	Chairperson: Prof. Hoffmann Deputy chairperson: Prof. Ukena
Prostate	**Head and neck tumours (module)**	**Neuro-oncological tumours (module)**	**Paediatric Oncology (module)**	**Soft tissue sarcoma (module)**
Chairperson: Prof. Burchardt Deputy chairperson: Prof. Fichtner	Chairperson: Prof. Iro Deputy chairperson: Prof. Ehrenfeld	Chairperson: Prof. Schlegel Deputy chairperson: Prof. Stummer	Chairperson: Prof. Eggert Deputy chairperson: Prof. Jürgens	Chairperson: Prof. Hohenberger Deputy chairperson: Prof. Grünwald

OnkoZert
Director: A. Kämmerle

Steering Certification	**Innovation/ Data management**	**Experts**

Certificate Awarding Committee

Legislative – Executive – Judiciary

The certification system consists of the legislative, executive and judiciary. The Certification Committee is the legislative. It has on average 30 representatives from scientific societies, professional associations, working groups and self-help. It draws together expertise from all medical specialties that treat oncological patients. The representatives draw up the catalogue of requirements and, by extension, the tumour-specific requirements based on the German evidence-based guideline certification requirements. Oncological experts check the implementation of the requirements in the audit process (executive).

They are non-voting members of the Certification Committee. Hence, there is a clear separation between legislative and executive. The auditor-physicians have undergone special training for their audit activities.
The decision about awarding a certificate (judiciary) is taken in another, independent body, the "Certificate Awarding Committee". Three trained experts are responsible for each procedure. In their evaluation they are free and independent. The Committee awards the certificates solely on the basis of the centre's presentation and the audit documentation drawn up by the experts.

Areas of responsibility within the Certification System

Scientific societies / Professional associations / Working groups	The German Cancer Society (DKG) is the initiator and designer of the certification system. All oncological scientific societies, working groups and professional associations come together under the DKG umbrella. Together they lay down the specialist requirements for certification and the further development of the certification system.
Certification Committee (Legislative)	The main task of the Certification Committee is the drawing up, further development and interpretation of the Specialist Requirements (certification criteria). The Certification Committee is empowered to make changes to the Specialist Requirements..
Certificate Awarding Committee (Judiciary)	The Certificate Awarding Committee is a separate, independent body from the audit procedure. Based on the audit documentation prepared by the experts, it verifies the proper conduct of each individual certification procedure. The Certificate Award Committee must approve the issuing of a certificate..
OnkoZert and Experts (Exekutive)	The experts administer and steer the certification system. Experts are individuals who are qualified to verify the Organ Cancer Centres on site and are recognised in this capacity by the German Cancer Society (DKG).

1.2 Health policy framework conditions

a) National Cancer Plan

The role of the certification system within the National Cancer Plan

The National Cancer Plan was jointly launched on 16 June 2008 by the Federal Ministry of Health (BMG), the German Cancer Society (DKG), German Cancer Aid (DKH) and the Association of German Tumour Centres ADT) to address problem areas in early cancer detection and cancer care. Efforts have been successful in securing the federal Laender, health insurance funds, pension funds, service providers, industry and patients' associations as committed cooperation partners in order to further develop the areas of early cancer detection and cancer care. Together, they focus their efforts on enabling all the stakeholders involved in fighting cancer to more effectively coordinate their activities and implement them in a targeted manner.

For the four action areas in the National Cancer Plan, expert groups have drawn up a total of 13 documents that specify the goals and the related implementation recommendations. The results are regularly monitored by the Federal Ministry of Health.

Goal 5 has to do with the certification of oncological treatment facilities. The target document gives a definition of certified centres for the first time. According to it certified centres are "a network of qualified and jointly certified, interdisciplinary, trans-sectoral and possibly multiple-location facilities that... represent, if possible, the entire chain of health care for those affected..." [1]

The 3-tier model of oncological care /National Certification Programme ofGerman Cancer Aid and the GermanCancer Society

Deutsche Krebshilfe HELFEN. FORSCHEN. INFORMIEREN. DKG Krebsgesellschaft

In line with the different tasks of oncological facilities the certification system distinguishes between three certification levels: Organ Cancer Centres (C) are centres that specialise in one organ or one specialty, Oncology Centres (CC) focus on several organs or specialties and Comprehensive Cancer Centres (CCC) which are leading Oncology Centres with major research aims, specifically for rare-cancer diseases and special issues.



The Organ Cancer Centres make up the broad basis of, if possible, nationwide care for prevalent tumour entities, for instance breast or colorectal cancer. By contrast, the Oncology Centres require a higher level of specialisation as this is where the expertise for several and, above all, rare diseases is bundled. Hence nationwide cover is neither possible nor mandatory. The Comprehensive Cancer Centres, which are audited by German Cancer Aid, focus on developing innovative treatments and drawing up new standards. Hence, they are even more centralised and there are just a few in Germany. They make up the narrow tip of the pyramid

However, for the entire model it can be said that patient care meets the same medical quality requirements irrespective of the health care structure, i.e. irrespective of the institution and its position in the 3-tier model, in which treatment is provided. [2]

The quality circle in oncology

Thanks to the initiative of the National Cancer Plan (NKP), a quality circle has been established in oncology which has taken on a pioneer role both in German and in European health care. The starting point of the quality circle are evidence-based guidelines (Goal 6 NKP) that reflect the latest scientific knowledge. The central recommendations (quality indicators) in these guidelines are the precondition for the certification of centres in the 3-tier model (Goal 5 NKP). The centres' treatment data (Goal 8 NKP) generated from the Clinical Cancer Registry are evaluated and notified back to the guideline groups. This gives them important information on the degree of implementation of the guideline contents in daily clinical practice. The evaluations are also fed back to the certified centres. [3]





The centres can then compare their own results with the results of all other centres. They can view their development over time and, more particularly, discuss any abnormal quality indicator/key figure results in the audit with experts and lay down suitable quality improvement measures.

With the outlined quality circle of the National Cancer Plan, the gold standard of quality assurance, the plan-docheck-act cycle, has become firmly established in daily oncological practice. For patients it leads to transparent presentation, reflection and – where necessary – quality improvements. [4]

b) European Cancer Centres

The growth in the number of Oncology Centres in other German-speaking countries testifies to the fact that the certification system is increasingly attracting attention beyond Germany's borders, too. Moreover, on the European level there are a number of initiatives that look at quality assurance in oncology (see c). Both of these developments led to the establishment of the European Cancer Centre (ECC) Certification Programme by the German Cancer Society in 2016 (<https://www.krebsgesellschaft.de/gcs/european-cancer centres.html>).

EUROPEAN CANCER CENTRES

In the context of the European certification system the goals of the certification programme (quality circles) can now be implemented Europe-wide and the quality of oncological care will be cross-nationally comparable. The further development of the European Certification Programme in cooperation with scientific societies from member states will be a central topic for the certification department in 2017.

c) European initiatives

Initiated by the European Commission an increasing number of projects address quality assurance in oncology. The German Cancer Society together with the federal Ministry of Health are actively involved in the implementations of these Joint Actions. Mention is made by way of example of the European Commission's Cancer Control Joint Action CanCon which focuses on the health care of cancer patients, including early cancer detection. The results of this Joint Cation were published in March 2017 as "European Guide on Quality Improvement in Comprehensive Cancer Control". The guide defines in the sense of the German Cancer Society's certified centres the necessities and pre-conditions for the implementation of oncological treatment networks (HYPERLINK „http://www.cancercontrol.eu/uploads/images/Guide/pdf/CanConGuide.pdf"). Another project initiated by the European Commission addresses quality assurance for breast cancer treatment on the basis of a European treatment guideline for early detection (European Commission Initiative on Breast Cancer" (ECIBC)). The German Cancer Society is the national contact organisation nominated by the Federal Ministry of Health as the German Cancer Society has the most comprehensive knowledge in this topic throughout Europe due to the decade long experiences with certified breast cancer centres.

Moreover, in 2017 the Joint Action for Rare Cancers (JARC) will start its working also including representatives of the German Cancer Society. The described developments show impressively that the topic of quality assurance in oncological care has gained momentum and significance on the European level and sustainable efforts are taken to establish an Europe-wide standardization of oncological care. Our certification system is way ahead of these developments and hence supports these developments with meaningful contributions.

1.3 History of the Certification System

National and international analyses of the treatment of breast cancer patients were the driving force behind the introduction of a certification system in Germany. Firstly, the studies revealed that there were medically inexplicable variations and deviations from recognised treatment guidelines in the current treatment of mammary carcinomas [6]. Secondly, there were major differences in the survival rate of breast cancer patients on the European level [7]. The Advisory Council on Concerted Action in the Health Care System, therefore, identified a need for action and called for more effective cooperation between all the stakeholders.

This prompted the German Cancer Society (DKG) and the German Society of Senology (Deutsche Gesellschaft für Senologie) to elaborate interdisciplinary requirements for the certification of breast cancer centres. The goal of certification was to improve the care of oncological patients thereby ensuring treatment of the highest possible standard at every stage of their illness.



Since 2003 certification has been based on a catalogue of requirements in which this idea of the comprehensive care of oncological patients, i.e. the medical care of patients from diagnosis over therapy to aftercare, is presented as specialist requirements that are the prerequisite for certification. This led to a shift in paradigms from the mono-speciality approach to interdisciplinary and multi-profession cooperation between all medical specialties. In the years that followed this network concept was extended to other tumour entities. The breast cancer centres were the model behind the emergence of the organ cancer centres for frequent tumour entities that are well-known today

In the course of the further development of this overall concept and the launch of the National Cancer Plan, the 3-tier model of Organ Cancer Centres (C), Oncology Centres (CC) and Comprehensive Cancer Centres (CCC) was set up. Certified centres – irrespective of the level – are networks of inpatient and outpatient facilities in which all medical specialties involved in the treatment of a cancer patients work closely together

In this context the certified centres must regularly prove that they meet the specialist requirements for tumour treatment (audit) and also have an established quality management system. The patient must be able to directly feel the benefits of an Oncology Centre.



What is an Oncology Centre?

An Oncology Centre consists of several organs or medical disciplines (definition in the National Cancer Plan). This means that the Centre must prove that it has sufficiently large scope to be eligible for certification.

This is verified during the audit with the help of a catalogue of requirements for the special tumour entity and explicitly stated in the published certificate.

Two important goals are achieved: firstly, it prevents clinics or surgeries from describing themselves as Oncology Centres although they only cover a small part of the oncological spectrum.

Secondly, the precise identification of the scope on the certificate ensures that the patient can see that no noncertified tumour entities come under the quality seal of an Oncology Centre [8]. This ensures fair and necessary transparency in the interests of the patient. Optimum cancer treatment can only be achieved in a certified network through cooperation between different disciplines and departments that input their expertise, for instance, in the tumour conferences. Certification does not specify how this exchange is to work in tumour conferences. Only the functionality and results of interdisciplinary agreements are audited. This allows the centres to organise their structures as they see fit.



1.4 Timeline

The timeline for the certification of an Oncology Centre (OC) is determined by a number of factors which influence the duration and scale of the preparations. What is important is, of course, the size of the OC and, by extension, the number of health care units to be included in the network to be certified. But also the survey of experts, the number of which may vary between 2 and 8 individuals depending on the audit, must be successfully coordinated.



7th month | 8th month | 9th month | 10th month | 11th month | 12th month

Drawing up the audit plan
Duration:
approx. 1-2 weeks

In consultation with the clinic and the experts OnkoZert draws up the audit plan. This contains the timeline for the on-site visual inspection of the individual areas and premises of the clinic..

On-site audit
Duration: approx. 2 days

In line with the audit plan the central areas of the Oncology Centre and the tumour entities identified in the scope are examined on the organ level. The audit ends with a recommendation by the experts to award or not award the certificate. In this context organ-specific differentiations are possible..

Preparing the audit report
Duration:
approx. 2-3 weeks

On conclusion of the on-site procedure the experts draw up audit reports for the central structures and the individual organs. The recommendation about the award of a certificate is formulated in writing..

If any non-compliance with the requirements in the catalogue is observed during the on-site audit, the expert pronounces a deviation. The centre then has three months to remedy this starting from the audit day.

Remedying deviations
Duration:
approx. 3 months

The expert remedies the deviations. This can be done by examining the documentation (inspection of evidence submitted) or a post-audit (renewed on-site audit). Positive remedying is the precondition for the award of the certificate.

Remedying deviations
Duration:
approx. 1-2 weeks

The entire audit documentation is sent for evaluation to the Certificate Awarding Committee. Based on the audit documentation this body, which is independent of the audit, takes a definitive decision about the award of the certificate.

Evaluation Certificate Award Committee
Duration:
approx. 2-3 weeks

After initial certification the certificate is valid for 3.5 years. After receiving the certificate the clinic may use the designation “Onkologisches Zentrum mit Empfehlung der Deutschen Krebsgesellschaft e. V.” (Oncology Centre with the recommendation of the German Cancer Society).

Certificate issue / dispatch
Duration: approx. 1 week

Certificate Oncology Centre

The certificate of an Oncology Centre consists of the main certificate and one annex. The Annex presents the scope of the Oncology Centre, which indicates the organ areas which can be treated in a quality assured and interdisciplinary manner in line with the requirements of the certification system. **Further information at http://www.ecc-cert.org**

DKG KREBSGESELLSCHAFT

Certified Oncology Centre

The independent certification institute OnkoZert herby attests that the

Oncology

Example street 10

represented by

Herrn Prof. D

meets the quality
to be met by Onco
Cancer Society. Th
the annex to the c

The Oncology Cent
designation

Oncology Ce
Deutsche Kre

First certification:
Validity:
Registration numb

Prof. Dr. W. Schmie
President
German Cancer So

Deutsche Krebsgesellschaft e.V.
Kuno-Fischer-Straße 8
14057 Berlin
Tel. (030) 322 93 29 0
E-Mail: service@krebsgesellschaft.de
www.krebsgesellschaft.de

EUROPEAN CANCER CENTRES

Certified Oncology Centre

The Independent Certification Institute OnkoZert hereby attests that the

Oncology Centre Example

within the Hospital Example
Example street 100, 1234 Example town, Example Country

represented by

Prof. Dr. med. M. Example

fulfills the quality criteria of the „Technical and Medical Requirements for Oncology Centres" within the European Cancer Centre Certification System.

The Centre Example is, therefore, given the title

Certified European Oncology Centre

Initial certification: 01.01.2017
Period of validity: 01.07.2020
Registration number: FAO-Z360

www.ecc-cert.org

Prof. Dr. U. Graeven
Speaker
Certification Commission for Oncology Centres

Prof. Dr. H. Lang
Deputy Speaker
Certification Commission for Oncology Centres



DKG KREBSGESELLSCHAFT

Annex to the Certificate Oncological Centre

Oncology Centre Example city

Example street 10

Validity period:
Registration number

Scope

The scope of an Onc
independently by ea
the certification outc
validity term of the r
www.oncomap.de.

Tumour entity / Or
Colon/rectum
Pancreas
Stomach (S)
Liver (S)
Oesophagus
Other gastroin (Bile ducts, primar neuroendocrine tu
Endocrine mal (including thyroid,
Breast
Gynaecologica (Cervix, uterus, ov
Testicles, peni
Kidney
Bladder
Head and neck (Mouth, pharynx,

(T) = preparing to become

Deutsche Krebsgesellschaft e.V.
Kuno-Fischer-Straße 8
14057 Berlin
Tel. (030) 322 93 29 0
E-Mail: service@krebsgesellschaft.de
www.krebsgesellschaft.de

EUROPEAN CANCER CENTRES

Attachment to the Certificate Oncology Centre

Oncology Centre Example

Example street 100, 1234 Example town, Example Country

Period of validity: 01.07.2020
Registration number: FAO-Z360

Scope

The scope of Oncology Centres is determined individually by each Centre. The scope can change during the period of validity of the main certificate. The actual valid scope is published under www.oncomap.de.

Tumor entity / Organ
Colon/rectum
Pancreas
Stomach (F)
Liver (F)
Oesophagus
Other gastrointestinal tumors (Bile ductus, gastrointestinal tumours, neuroendocrine tumours)
Endocrine malignomas (including thyroid, neuroendocrine tumours, adrenal gland)
Breast
Gynaecological Tumors (T) (Cervix, uterus, ovary including BOT, vulva, vaginal Tumours)
Testicles, penis
Kidney
Bladder
Head and neck tumours (T) (Mouth, pharynx, larynx)

(T) = in preparation (transit) for Organ Cancer Centre/Module
(F) = Focus

www.ecc-cert.org

1.5 Definitions

Certification as an Oncology Centre is dependent on fulfilling specific requirements. Within the framework of structural requirements, different evidence levels have been defined for the individual tumour entities:

Z =	**Organ Cancer Centre** For Organ Cancer Centres the certification criteria are presented in independent catalogues of requirements. They contain all the organ-specific specialist requirements. The certification of an Organ Cancer Centre is also possible separate from an Oncology Centre. Breast cancer, colon/rectum cancer, gynaecological cancer, skin cancer, lung cancer, prostate cancer
M =	**Module** The requirements to be met by modules are compiled in the catalogue of requirements for Oncology Centres and in the organ-specific catalogues of requirements of the modules. Hence, certification of a tumour entity is only possible in combination with certification as an Oncology Centre. The exceptions here are the pancreas, stomach and liver cancers. These can also be linked to a colon cancer center (visceral oncology center). Head and neck tumours, neuro-oncology tumours, pancreas cancer, stomach cancer, liver cancer, peadiatric cancer, esophagus cancer und sarcomas
S =	**Focus** For foci the requirements in the document "Definition of Foci" must be met and presented in the cross-organ "Tumour Entity" annex. The foci are part of the Oncology Centre.. I Oesophagus, stomach, bile ducts, primary liver tumours, GIST, neuroendocrine tumours II Malignant tumours of the musculoskeletal system (including soft tissue sarcomas) III CUP, locally treatable metastases (insofar as the primary tumour is not being treated in an Organ Cancer Centre), special palliative questions in advanced metastasised tumours IV Endocrine malignancies (including thyroid, neuroendocrine tumours, NN) V Lymphomas, leukaemia, plasmocytomas and other haematological systemic diseases VI Kidney, adrenal gland, bladder, testicles and penis Tumours included in the focus list may not be included in the scope of the Oncology Centre as transit (= "T") but only as a focus.
T =	**Transfer/ transit centre** If an Organ Cancer Centre or a module is unable to meet the minimum requirement for primary cases, this entity has the option of being given temporary certification within the framework of the Oncology Centre. In this context the objective is advancement from evidence level "T" to "Z" or "M" within three years. Transit centres are presented in the "Tumour Entity" Annex and are thus part of the Oncology Centre.
V =	**Care** (not in the scope of the Oncology Centre) Tumour entities, treated at the location, but which are not however put forward for or do not meet the certification requirements are to be labelled as "V".
n =	**No treatment at the location** If a tumour entity is not to be treated at the location, i.e. there will be no treatment in line with the centre's concept of a primary case, then evidence level "n" applies.

Fulfilment of the primary case requirement is an important basis for certification as an Organ Cancer Centre/module. A primary case of a centre is deemed to be a patient who receives most of his/her treatment in the Centre or in the certified network.

The primary case is counted when the first diagnosis is made. The exact definition of the primary case and the minimum number of cases to be met do, however, differ depending on the tumour entity and evidence level stipulated in the respective catalogues of requirements or compiled in the Certcalculator..

1.6 Approval requirements

The Certcalculator determines the individual scope of each Oncology Centre on the basis of the evidence levels. The Certcalculator examines, as the official part of the certification request and the catalogue of requirements, whether the underlying structural preconditions have been met. The precise structural requirements for Oncology Centres are explained in more detail in the table below:

	First certification	Recertification (after 3 years)
Organ Cancer Centres (Z) and/or modules (N)	2	3
The expertise acquired when setting up Organ Cancer Centres/Modules should be used for the other areas of the Oncology Centre. The tumour entities with evidence level Z/M are subject to stiffer conditions and should, therefore, assume a pioneer role.		
Scope in accordance with the Certcalculator $Z + M + S + T \geq 50\%$	≥ 50 %	≥ 50 %
An Oncology Centre is not an individual discipline but a care unit in which the major share of cancer diseases can be treated in a quality assured manner.		
Scope in the scale of care $\frac{Z + M + S + T}{Z + M + S + T + V} \geq 70\%$	≥ 70 %	≥ 70 %
The proportion of tumour entities treated in the clinic of the Oncology Centre but which cannot be certified may not be more than 30% according to the Certcalculator..		
Recognition of evidence level "T"	Maximum 2 organs per centre up to recertification	Maximum 1 organ per centre for a further 3 years after recertification
The Oncology Centre supports the gradual advancement to certified Organ Cancer Centres/Modules. Selected tumour entities may be included for a defined period of time in the Oncology Centre without all requirements being met. Designation as a certified Organ Cancer Centre is not possible for these transit centres.		

1.7 The "Certcalculator"

Annex EB Version G1.1 (audit year 2017 / indicator year 2016)

DKG Krebsgesellschaft

Reg.-No. [1]	FAO-Z360
Centre	Oncological Centre Example city
Location	Klinikum Example city
Contact [1]	Dr. Mustermann

Record date (dd.mm.yyyy) [1]	01.01.2017
Date of first certification	01.01.2017
Indicator year	2016

Organ Cancer Centre | Module | Focus | Transit

Minimum target primary cases

	Tumour entity/localisation	New cases of cancer [2]	Proportion in %	Verification level/ minimum primary cases Z	M	S	T	Centre details: Detection level Z, M, S, T, V, n	Primary cases last calendar year	Scope OC-without V
1	**Colon/rectum**	65.390	16,44%	50			25	Z	50	16,44%
2	**Pancreas**	14.960	3,76%		25		13	M	25	3,76%
3.1	**Stomach (S1)**	15.870	3,99%		30	— [3]	15	M	30	3,99%
3.2	**HCC (S1)**	8.020	2,02%		30	— [3]	15	M	30	2,02%
4	**Oesophagus (S1)**	6.180	1,55%			— [3]		S	5	1,55%
5	**Other gastrointestinal tumours (S1)** (bile ducts, neuroendocrine tumours, tumours of the small intestine)	4.650	1,17%			— [3]		S	5	1,17%
6	**Endocrine malignancies (S4)** (incl. thyroid, adrenal gland)	5.870	1,48%			— [3]		S	5	1,48%
7	**Lymphoma (S5)**	15.780	3,97%			— [3]		V		—
8	**Leukaemia (S5)**	11.420	2,87%			— [3]		V		—
9	**Haematological systemic diseases (S5)** (Plasmozytom, a.o.)	5.630	1,42%			— [3]		V		—
10	**Breast**	72.180	18,15%	100			50	Z	100	18,15%
11	**Gynaecological tumours** (cervix, uterus,ovaries incl. BOT, vulva, vaginal tumours)	26.280	6,61%	50			25	T	25	6,61%
12	**Skin** (melanoma, malignant epithelial tumours)	17.800	4,48%	40			20	n		—
13	**Prostate**	63.440	15,95%	100			50	V		—
14	**Testicles, penis (S6)**	5.660	1,42%			— [3]		S	5	1,42%
15	**Kidney (S6)**	14.500	3,65%			— [3]		S	5	3,65%
16	**Bladder (S6)**	15.970	4,02%			— [3]		S	5	4,02%
17	**Musculoskeletal tumours (S2)** (including soft tissue sarcomas)	1.000	0,25%			— [3]		n		—
18	**Head and neck tumours** (mouth, pharynx, larynx)	17.130	4,31%		75		37	T	37	4,31%
19	**Neuro-oncological tumours**	10.000	2,51%		100		50	n		—
	Total	**397.730**	**100,00%**					**Total (without „V")**	**277**	**68,55%**
20	**Lung**	49.530	12,45%	200			100	V		—
	Total with Lung	**447.260**	**112,45%**					**Total with Lung (without „V")**	**277**	**68,55%**

Selected evidence level | Centre cases | Inclusion in scope

[1] Reg.No. Record date and contact information are mandatory

[2] Modified RKI list 2008

[3] At the present time no minimum requirements defined for primary cases for verification level "S"

Overall outcome

Area of application (at least 50%)	68.55%	Z+M+S+T
Scale of care in % (no min. requirements)	92.76%	Z+M+S+T+V
Area of application within the scope of care (at least 70%)	73.91%	Z+M+S+T
Number of Organ Cancer Centres / modules (sum Z+M)	3	Z+M+S+T+V
Number of transit centres (sum T)	2	
Preconditions met, processing complete	**yes**	

2. DATA – DKG CERTIFICATION SYSTEM

2.1 Overview of DKG certificates (Status 31.12.2016)

	ORGAN CANCER CENTRES						MODULES						
	Breast	Colon/rectum	Gyn.	Skin	Lung	Prostate	Head & neck	Neuro	Pancreas	Stomach	Liver	Visceraloncol. Centre	Oncology Centre
Ongoing first certification	4	7	6	5	5	7	6	8	5	4	5	---	6
Certified centres	230	280	133	55	45	103	41	26	91	10	16	91	97
Certified locations	280	288	135	55	53	104	43	27	93	10	18	94	109
Primary cases total	54.230	26.660	12.306	11.209 [2]	17.731	19.932	6.273 [3]	5.456 [4]	4.070	---	---	---	---
Primary cases per centre	236	95	93	204	394	194	153	210	45	---	---	---	---
Primary cases per location	194	93	91	204	335	192	146	202	44	---	---	---	---
New cases of cancer [1]	70.170	62.230	26.140	20.820 [2]	52.520	63.710	15.628 [3]	---	16.730	---	---	---	---
Overall rate [1] 31.12.2015	74,6%	41,4%	43,6%	50,8%	32,9%	29,6%	37,5%	---	22,9%	---	---	---	---
Locations abroad	11	10	9	4	2	7	4	1	6	1	0	6	6

[1] Results according to ICD-10; estimated number of new cases of cancer in Germany 2012
[2] Limited to malignant melanoma
[3] Head-neck-tumours new cases: mouth and throat C00-C06, C14, larynx C32
[4] Neuro-oncological tumours C70-C75; counted according to ICD-O

2.2 Clinics in the Certification System

On 31.12.2016 a total of 442 hospitals with at least one valid certificate were represented in the certification system of the German Cancer Society. Including the 16 clinics abroad, 426 out of 1,082 hospitals in Germany, which treated at least 100 cases with a malignant main diagnosis (C00-C97) in 2012, held one or more DKG certificates [9].

The differentiated presentation by "number of certified Organ Cancer Centres/Modules" is of importance when it comes to the Oncology Centre because at least two Organ CancerCentres/ Modules must be proved for first certification as an Oncology Centre.

For the purposes of recertification after 3 years this requirement is raised to 3 Organ Cancer Centres/ Modules. As per 01.01.2017 a total of 176 clinics in Germany can, therefore, be recertified as Oncology Centres. Compared with the previous year this means a growth of 12 clinics.

Federal Land	Clinics total	Number of certified Organ Cancer Centres (Z) / Modules (M) per clinic				Oncology Centres (locations)
		1 Organ	2 Organs	3 Organs	≥ 4 Organs	
Baden Württemberg	63	22	9	7	25	20
Bavaria	57	15	11	5	26	20
Berlin	18	6	2	5	5	6
Brandenburg	13	9	0	2	2	2
Bremen	6	3	2	0	1	1
Hamburg	6	2	0	2	2	2
Hessen	30	10	7	6	7	6
W-Mecklenburg Pomerania	6	1	1	0	4	4
Lower Saxony	37	12	9	7	9	4
North Rhine-Westphalia	91	45	17	11	18	22
Rheinland-Pfalz	21	9	5	0	7	4
Saar	6	4	1	0	1	1
Sachsen	26	16	5	0	5	4
Saxony-Anhalt	17	10	4	2	1	2
Schleswig-Holstein	16	6	6	2	2	2
Thuringia	13	6	3	0	4	3
Locations abroad						
Italy	2	2	0	0	0	0
Austria	4	1	2	0	1	1
Switzerland	10	1	2	0	7	5
Total	442	180	86	49	127	109
	100%	40,7%	19,5%	11,1%	28,7%	24,7%
			59,3% (= 262 clinics) Precondition first certification OC			
			---	39,8% (= 176 clinics) Precondition OC after 3 years		
Status 31.12.2015	442	193	85	60	104	94
	100%	43,7%	19,2%	13,6%	23,5%	21,3%
Status 31.12.2014	446	205	93	56	92	81
	100%	46,0%	20,9%	12,6%	20,6%	18,2%
Status 31.12.2013	444	213	99	57	75	62
	100%	48,0%	22,3%	12,8%	16,9%	14,0%
Status 31.12.2012	439	221	98	61	59	52
	100%	50,4%	22,3%	13,9%	13,4%	11,8%
Status 31.12.2011	413	221	105	42	45	41
	100%	53,5%	25,4%	10,2%	10,9%	9,9%
Status 30.11.2010	378	216	105	37	20	14
	100%	57,1%	27,8%	9,8%	5,3%	3,7%

Organe = Organ Cancer Centres (Z) — Breast, colorectal, gyn, skin, lung, prostate

Modules (M) — Head and neck, neuro, pancreas, stomach, liver

2.3 University clinics - Comprehensive Cancer Centres / Oncology Centres

The presentation of university centres refers to the status as per 31.12.2016.

CCC ... Comprehensive Cancer Centres, recognised by German Cancer Aid (DKH)

OZ ... Oncology Centres, recognised by the German Cancer Society (DKG)

	Universities (in Germany)
Universities total	33
CCC and OZ	16
Only CCC	1
Only OZ	14
Not CCC and not OZ	3

Multi-location university structures

Some universities are "Multi-location structures". Cooperation may refer to university status, to the composition of the Comprehensive Cancer CentreCenters or to the Oncology Centre. The total number of 13 recognised CCCs comprises 14 university clinics and 16 individual clinics.

University	Individual clinics
Charité Berlin [1)]	Campus Mitte; Campus Virchow-Klinikum; Campus Benjamin-Franklin; Campus Buch
Universität Gießen/ Marburg [2)]	location Gießen; location Marburg
Ruhr Universität [3)]	Knappschaft Bochum; SJ Bochum; Marienhospital Herne; BG- Bergmannsheil; SJ Dortmund Hörde*); Marien-Hospital Witten*); St. Elisabeth-Hospital; St. Maria Hilf; Klinik Blankenstein *) non-university facilities, however in a group with the university Oncology Centre individual clinics of the Univ.-Ruhr without an oncology focus, are not mentioned
Universität Bonn / Universität Köln [4)]	Together, Bonn and Cologne universities constitute a CCC
Universität Schleswig Holstein [5)]	Campus Kiel; Campus Lübeck
Universität München [6)]	Campus Großhadern; Campus Innenstadt
Comprehensive Cancer Center München [7)]	Consists of the two Munich universities: TU Munich und LMU Munich
Comprehensive Cancer Center Erlangen-EMN [8)]	Encompasses as a CCC with the Social Foundation Bamberg and the Klinikum Bayreuth two non-university locations. As in this "Organ Cancer Centres in universities" overview only university facilities are considered, they are not taken into account in the evaluation
Comprehensive Cancer Center Tübingen Stuttgart [9)]	Consists of the University Hospital Tübingen and the Robert-Bosch-Hospital Stuttgart
University Cancer Center-Regensburg [10)]	The Oncology Centre consists of the locations Universitätsklinikum and Caritas-Krankenhaus St. Josef Regensburg
Breast Cancer Centres NRW [11)]	Breast Cancer Centres of Aachen and Münster universities are recognised under the NRW-certification system

Comments on the list "Organ Cancer Centres in Universities"

- When only one clinic has "OC" or "CCC" status in a multi-location university structure, this is indicated in the table for the overall university.
- Other universities are also named, which are part of the ongoing certification procedure „Oncology Centre". As per 01.03.2017 one of these is the University Hospital Gießen.
- In the case of universities and Oncology Centres with several individual clinics (multi-locations), an Organ Cancer Centre need not be represented in each individual clinic. The presentation for a clinic location can be accessed on www.oncomap.de.

Organ Cancer Centres in universities (clinic groups – not individual clinics)

University (by Federal Land)	Federal Land	CCC	Oncology Centre	University multi-location	Organ Cancer Centres						Modules				
					Breast	Colon/rectum	Gyn	Skin	Lung	Prostate	KHT	NOZ	Pancreas	Stomach	Liver
Charité Berlin	BE	■	■	■[1]	■	■	■	■	■	■	■	■	■	■	■
Universität Freiburg	BW	■	■		■	■	■	■	■		■	■	■		
Universität Heidelberg	BW	■			■		■	■	■						
Universitätsmedizin Mannheim	BW		■		■	■	■	■		■	■				
Universität Tübingen	BW	■[9]	■		■	■	■	■		■	■	■	■	■	
Universität Ulm	BW	■	■		■	■	■	■		■	■		■		■
Universität Erlangen	BY	■[8]	■		■	■	■	■		■	■		■		
Universität München	BY	■[7]	■	■[6]	■	■	■		■	■		■	■		
Rechts der Isar - TU München	BY	■[7]	■		■	■	■	■		■	■	■	■		
Universität Regensburg	BY		■[10]		■	■	■	■		■	■	■	■		■
Universität Würzburg	BY	■	■		■	■	■	■		■	■	■	■		
Universität Frankfurt	HE	■	■		■	■	■	■	■	■	■	■	■	■	■
Universität Gießen und Marburg Standort Gießen	HE		□	■[2]		■							■	■	
Standort Marburg	HE		■	■[2]	■	■	■	■		■	■		■		
Universität Hamburg-Eppendorf	HH	■	■		■	■	■			■	■				
Universität Greifswald	MV		■		■	■	■	■		■		■	■		
Universität Rostock	MV		■			■				■	■		■		
Universität Göttingen	NI		■		■	■	■		■						
Medizin. Hochschule Hannover	NI		■		■		■	■		■	■				■
Universität Aachen	NW		■		■[11]	■	■	■			■	■	■	■	■
Ruhr Universität	NW		■	■[3]	■	■	■	■		■	■	■	■		
Universität Bonn	NW	■[4]	■		■		■	■			■	■	■		
Universität Düsseldorf	NW	■	■		■	■	■	■		■	■		■		
Universität Essen	NW	■	■		■		■	■	■	■	■	■	■		
Universität Köln	NW	■[4]	■		■	■	■	■	■	■	■	■	■		
Universität Münster	NW		■		■[11]		■	■		■	■	■	■		
Universität Mainz	RP	■	■		■	■	■	■		■		■			■
Universität Schleswig Holstein Campus Kiel	SH		■	■[5]	■	■	■	■		■	■		■		
Campus Lübeck	SH		■	■[5]	■	■	■	■			■		■		
Universität des Saarlandes	SL				■	■									
Universität Dresden	SN	■	■		■	■	■	■		■			■		
Universität Leipzig	SN		■				■	■		■	■	■			
Universität Halle (Saale)	ST				■		■	■							
Universität Magdeburg	ST									■					
Universität Jena	TH		■		■	■	■	■		■	■				■

Legend ■ certified □ in the ongoing certification process

2.4 Development of Certified Centres 2008 - 2016

		Organ Cancer Centres						Modules					Oncology Centre	Total number
		Breast	Colon/rectum	Gyn	Skin	Lung	Prostate	Head and neck	Neuro	Pancreas	Stomach	Liver		
31.12.2016	Locations	280	288	135	55	53	104	43	27	93	18	10	109	1215
	Centres	230	280	133	55	45	103	41	26	91	16	10	97	1127
31.12.2015	Locations	279	274	125	47	49	98	36	22	79	5	2	94	1108
	Centres	228	265	123	47	42	97	34	21	77	3	2	82	1023
31.12.2014	Locations	277	276	112	43	44	95	26	16	68	-	-	81	1038
	Centres	224	267	110	43	38	94	24	15	67	-	-	69	951
31.12.2013	Locations	274	266	100	41	42	95	13	8	50	-	-	62	951
	Centres	218	257	98	41	38	94	11	7	50	-	-	54	868
31.12.2012	Locations	267	257	80	39	38	92	10	4	43	-	-	52	882
	Centres	212	247	78	39	34	91	8	3	42	-	-	44	798
31.12.2011	Locations	261	233	67	32	27	81	3	-	29	-	-	41	774
	Centres	204	223	67	32	26	80	3	-	28	-	-	33	696
31.12.2010	Locations	258	199	53	30	18	64	-	-	5	-	-	14	641
	Centres	200	188	53	30	18	63	-	-	4	-	-	11	567
31.12.2009	Locations	250	152	32	19	8	45	-	-	-	-	-	5	511
	Centres	195	141	32	19	8	44	-	-	-	-	-	3	442
31.12.2008	Locations	232	99	11	-	-	24	-	-	-	-	-	3	369
	Centres	181	89	11	-	-	23	-	-	-	-	-	1	305

Breast



Colon/rectum



Lung



Skin



Prostate



Gynaecological tumours



Head and neck tumours



Neuro-oncological tumours



Pancreas



3. DATA – ONCOLOGY CENTRES

3.1 Development of Oncology Centres

2015 was again characterized by intensive activity in the certification system Oncology Centers. A total of 14 certificates were awarded for Oncology Centres.

This dynamic is continuing in 2017as well. At the present time there are 6 centres in the ongoing certification procedure

Oncology Centres



3.2 List of Oncology Centres

113 locations in total are mentioned in the list. Besides the 109 locations which had a valid certificate on 31.12.2016, there are four more locations listed which received their certificate as an Oncology Centre for the first time at the beginning of 20177 (up to 01.03.2017).

The weekly status is accessible on www.oncomap.de.

oncoMAP

Clinic /Location Oncology Centre (by Federal Land)	**Federal Land**	**Multi-location Oncology Centre**	**Colon/rectum**	**Pancreas**	**Stomach**	**Liver**	**Oesophagus**	**Other gastrointestinal tumours**	**Endocrine malignomas**	**Lymphoma**	**Leukaemia**	**Haematological systemic diseases**	**Breast**	**Gynaecological tumours**	**Skin**	**Prostate**	**Testicles, penis**	**Kidney**	**Bladder**	**Musculoskeletal tumours**	**Head and neck tumours**	**Neuro-oncological tumours**	**Lung**
Klinikum Cottbus	BB		■	■	■	■	■	■					□	■	□	■	■	■	■		■		
Ruppiner Kliniken, Neuruppin	BB		■		■	■	■	■		■	■	■	■	■		□	■	■	■				
Charité Berlin Mitte	BE	■	■		■ᴹ		■	■		■			■	■	■	■	■	■	■		■		■
Virchow-Klinikum	BE	■	■	■	■ᴹ	■ᴹ	■	■	■	■	■	■		■				■		■	■	■	■
Benjamin-Franklin	BE	■	■	■	■ᴹ		■	■		■	■	■	■	■		■	■	■	■		■	■	
Evang. Waldkrankenhaus Spandau (Berlin)	BE		■		■	■	■	■		■	■	■	■	■						■			■
Gemeinschaftskranken-haus Havelhöhe (Berlin)	BE		■		■	■	■	■					■										□
HELIOS Klinikum Berlin-Buch	BE		■		■	■	■	■	■	■	■	■	■	□	□		■	■	■	■			
Caritas Krankenhaus Bad Mergentheim	BW		■		■					■	■	■	■			■							
Hegau-Bodensee-Klinikum Singen	BW		■		■					■			■	□		■		■					
Klinik Nürtingen	BW		■	□	■	■	■	■		■	■	■	■	■									
Klinikum Stuttgart Katharinenhospital	BW	■	■	■	■	■	■	■	■	■	■	■	■	■		■					■	■	
Bad Cannstatt	BW	■	■		■	■	■	■															
Klinikum Winnenden	BW		■	□	■		■			■	■	■	■			□							
Kreiskliniken Reutlingen	BW		■	■	■	■	■	■		■	■	■	■	■		■	■	■	■				
Kreiskrankenhaus Sigmaringen	BW		■		■				■	■			■			■	■	■					
Ludwigsburg-Bietigheim Klinikum Ludwigsburg	BW	■	■	■	■		■		■	■			■			■	■	■	■			■	
Krankenhaus Bietigheim	BW	■	■		■				■	■			■										
Ortenau Klinikum Lahr	BW	■	■	■	■	■	■	■	■	■	■	■	■				■	■	■				
Offenburg	BW	■	■							■	■	■	■	■		■	■	■	■				
Paracelsus-Krankenhaus Ruit	BW		■	□	■	■	■	■		■	■	■	■	□		■	■	■	■				
Robert-Bosch Stuttgart	BW		■		■		■			■	■	■	■	■									■
SLK-Kliniken Heilbronn	BW		■	■	■ᴹ	■ᴹ	■			■	■	■	■		■	■					■		■
St. Elisabeth Ravensburg	BW		■		■								■	■		□							

Clinic /Location Oncology Centre (by Federal Land)	Federal Land	Multi-location Oncology Centre	Colon/rectum	Pancreas	Stomach	Liver	Oesophagus	Other gastrointestinal tumours	Endocrine malignomas	Lymphoma	Leukaemia	Haematological systemic diseases	Breast	Gynaecological tumours	Skin	Prostate	Testicles, penis	Kidney	Bladder	Musculoskeletal tumours	Head and neck tumours	Neuro-oncological tumours	Lung
Stauferklinikum Schwäbisch Gmünd	BW		■		■	■	■	■	■	■	■	■	■	■									
Universität Freiburg	BW		■	■	■	■	■	■		■	■	■	■	■	■	□				■	■	■	■
Universität Mannheim	BW		■		■		■						■	■	■	■					■		
Universität Tübingen	BW		■	■	■[M]	■[M]				■		■	■	■	■	■	■	■	■	■	■	■	
Universität Ulm	BW		■	■	■	■[M]	■			■	■	■	■	■	■	■				■	■	□	
Barmherzige Brüder Regensburg	BY		■	■	■[M]	■[M]	■	■		■	■	■	■	□			■	■	■	■		■	■
DONAUISAR Klinikum Deggendorf	BY		■	■	■[M]								■	■		□	■	■	■			■	
HELIOS Amper-Klinikum Dachau	BY		■	□	■	■	■	■	■	■	■	■	■								□		
Klinikum Ansbach	BY		■		■	■	■	■					■	■		□							
Klinikum Aschaffenburg	BY		■	■	■	■	■	■		■	■	■	■	■		■	■	■					
Klinikum Bayreuth	BY		■	■	■	■	■	■	■	■	■	■	■	□	■		■	■	■				
Klinikum Bogenhausen	BY		■	■	■[M]											□		■					■
Klinikum Dritter Orden München	BY		■		■		■		■	■	■	■	■	■									
Klinikum St. Marien Amberg	BY		■		■								■	■		■		■	■				
Klinikum Traunstein	BY		■							■	■	■	■	■		■	■	■	■				
Rechts der Isar - TU München	BY		■	■	■		■		■	■	■	■	■	■	■	■				■	■	■	
REGIOMED Coburg	BY		■	■	■	■	■			■	■	■	■	■			■	■	■				
RoMed Klinikum Rosenheim	BY		■	■	■[M]								■	■		■			■				
Sozialstiftung Bamberg	BY		■	□	■	■	■	■	■	■	■	■	■	■			■	■	■				
St. Elisabeth Straubing	BY		■		■								■	■		■	■	■	■		■		
University Cancer Center-Regensburg Universität Regensburg	BY	■	■	■	■	■[M]	■	■	■	■	■	■			■					■	■	■	□
Caritas SJ Regensburg	BY	■	■		■								■	■		■		■	■				
Universität Erlangen	BY		■	■						■	■	■	■	■	■	■		■	■		■	■	
Universität München - Großhadern	BY		■	■	■	■		■	■				■	■		■		■	■			■	■
Universität Würzburg	BY		■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	

Clinic /Location Oncology Centre (by Federal Land)	Federal Land	Multi-location Oncology Centre	Colon/rectum	Pancreas	Stomach	Liver	Oesophagus	Other gastrointestinal tumours	Endocrine malignomas	Lymphoma	Leukaemia	Haematological systemic diseases	Breast	Gynaecological tumours	Skin	Prostate	Testicles, penis	Kidney	Bladder	Musculoskeletal tumours	Head and neck tumours	Neuro-oncological tumours	Lung
Klinikum Bremen-Mitte	HB		■	■	■	■	■	■		■	■	■	■	■	■	■					■		
Klinikum Fulda	HE		■	■						■	■	■	■	□		■					□		
Klinikum Kassel	HE		■	■	■	■	■	■		■	■	■	■	■	■						■	■	□
Lahn-Dill-Kliniken - Wetzlar	HE		■		■	■	■	■					■	■		□							
Nordwest - Frankfurt a.M.	HE		■	■	■	■	■	■					□			■							
Universität Frankfurt	HE		■	■	■[M]	■[M]		■					■	■	■	■					■	■	■
Universität Gießen/ Marburg - Marburg	HE		■	■				■		■	■	■	■	■	■	■	■	■	■		■		□
Asklepios Klinik Barmbek	HH		■	■	■	■	■	■		■			■	□			■						
Universität Hamburg-Eppendorf	HH		■							■	■	■	■	■		■	■	■	■		■		
HELIOS Kliniken Schwerin	MV		■	□	■[M]		■	■	■	■	■	■	■	■	■		■	■	■	■			
Klinikum Südstadt Rostock	MV		■	■	■	■	■	■	■	■	■	■	■	■									
Universität Greifswald	MV		■	■	■	■	■	■		■	■	■	■	■	■	■	■	■	■			■	
Universität Rostock	MV		■	■	■	■	■	■	■	■	■	■				■	■	■	■		■		
Klinikum Hildesheim	NI		■	■	■	■	■	■					■		■			■	■				
Klinikum Braunschweig	NI		■	■	■		■						■	■		■	■						
KRH Klinikum Siloah Hannover	NI		■	■	■					■	■	■	■			■		■					■
MH Hannover	NI		□		■	■[M]							■	■	■	□		■	■		■		
Pius Hospital Oldenburg	NI		■	■	■	■	■	■		■	■	■	■	■									■
Universität Göttingen	NI		■							■	■	■	■	■		□					□		■
Johaniter KH Bonn	NW		■		■		■		■	■	■	■	■[N]			■	■	■	■				■
Kliniken der Stadt Köln - Holweide	NW		■		■	■		■	■	■	■	■	■[N]	□				■	■		■		
Klinikum Dortmund	NW		■	□	■	■	■	■					■[N]	■	■	■					■		
Klinikum Gütersloh	NW		■		■	■	■	■	■	■	■	■	■[N]	■		■	■	■	■				
Knappschaft Dortmund	NW		■		■		■						■			■							□

Clinic /Location Oncology Centre (by Federal Land)	Federal Land	Multi-location Oncology Centre	Colon/rectum	Pancreas	Stomach	Liver	Oesophagus	Other gastrointestinal tumours	Endocrine malignomas	Lymphoma	Leukaemia	Haematological systemic diseases	Breast	Gynaecological tumours	Skin	Prostate	Testicles, penis	Kidney	Bladder	Musculoskeletal tumours	Head and neck tumours	Neuro-oncological tumours	Lung
MAgKs (Münsteraner Allianz gegen Krebs) Clemenshospital	NW	■	■		■		■	■		■			■[N]									■	■
Fachklinik Hornheide	NW	■								■					■					■	■		
Raphaelsklinik	NW	■	■	■	■		■	■	■	■							■	■	■				
Maria Hilf Mönchengladbach	NW		■		■		■		■	■	■	■				■	■	■	■		■		□
Ruhr Universität Knappschaft Bochum	NW	■	■		■	■	■	■		■	■	■									■	■	
SJ Bochum	NW	■	■	■	■	■	■	■							■								
SJ Dortmund	NW	■	■	■	■	■	■	■	■	■	■	■					■	■	■				
Marien-Hospital Witten	NW	■	■		■			■					■	■									
St. Anna Hospital Herne	NW	■	■	■	■	■	■	■		■			■										
St. Agnes-Hospital Bocholt	NW		■		■	■	■	■					■[N]	□		□	■	■	■				
St. Josef-Hospital Troisdorf	NW		■							■	■	■	■[N]	□		■	■	■	■				
Universität Aachen	NW		■	■	■[M]	■[M]	■	■		■	■	■	■[N]	■	■						■	■	
Universität Bonn	NW		□	■	■	■	■	■	■	■	■	■	■	■	■	□	■	■	■	■	■	■	
Universität Düsseldorf	NW		■	■					■	■	■	■	■	■	■	■					■		
Universität Essen	NW		□	■	■	■	■	■	■	■	■	■	■	■	■	■			■	■	■	■	■
Universität Köln	NW		■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
Universität Münster	NW		□	■	■	■	■	■	■	■	■	■	■[N]	■	■	■	■	■	■	■	■	■	
Barmherzige Brüder Trier	RP		■													■	■	■	■			■	■
Diakonissen-Stiftungs Speyer	RP		■		■	■	■	■	■	■	■	■	■	■									
Klinikum Ludwigshafen	RP		■	■	■					■	■	■	■		■	■					■		
Universität Mainz	RP		■			■[M]				■	■	■	■	■	■	■	■	■	■	■		■	
Univ. Schleswig Holstein - Kiel	SH		■	■	■	■	■	■					■	■	■	■					■		□
Lübeck	SH		■	■	■	■	■	■	■	■	■	■	■	■	■	□					■		□
Caritas Klinikum Saarbrücken	SL		■	□	■	■	■	■		■	■	■	■	□							■		
Klinikum Chemnitz	SN		■	□		■		■		■	■	■	■								■		■

Clinic /Location Oncology Centre (by Federal Land)	**Federal Land**	**Multi-location Oncology Centre**	**Colon/rectum**	**Pancreas**	**Stomach**	**Liver**	**Oesophagus**	**Other gastrointestinal tumours**	**Endocrine malignomas**	**Lymphoma**	**Leukaemia**	**Haematological systemic diseases**	**Breast**	**Gynaecological tumours**	**Skin**	**Prostate**	**Testicles, penis**	**Kidney**	**Bladder**	**Musculoskeletal tumours**	**Head and neck tumours**	**Neuro-oncological tumours**	**Lung**
Krankenhaus Dresden Friedrichstadt	SN		■	■	■[M]	■[M]	■	■					■	□		■					■		
Universität Dresden	SN		■	■	■	■	■	■					■	■	■	■	■	■	■				
Universität Leipzig	SN		□		■	■	■	■					□	■	■	■					■	■	
Krankenhaus Martha-Maria Halle-Dölau	ST		■	□	■	■	■	■		■	■	■				■	■	■	■				■
St. Elisabeth und St. Barbara Halle (Saale)	ST		■		■	■	■	■		■	■	■	■	□									
HELIOS Klinikum Erfurt	TH		■	■						■	■	■	■	■	■	■		■			■	■	
Klinikum Gera	TH		■	■	■		■						■		■	■			■				■
Universität Jena	TH		■		■	■[M]	■	■		■	■	■	■	■	■	■	■	■	■	■	■		
Barmherzige Schwestern Linz	A		■	■	■								■	■		■					■		
Inselspital Bern	CH		■	■	■[M]	■[M]			■				■	■	■	■	■	■	■	■	■		■
Kantonsspital Aarau	CH		■	□						■	■	■	■	■	□	■							
Kantonsspital Baden	CH		■	□	■	■	■	■	■	■	■	■	■	□		■	■	■	■				
Luzerner Kantonsspital	CH		■	■	■	■	■	■	■	■	■	■	■	■	□	■	■	■	■		■		
Universitätsspital Basel	CH		□		■	■	■	■					■	■	■	□					■		
Universitätsspital Zürich	CH		■							■	■	■	■	■	■	■				■	■	■	■

Legend

■ Organ Cancer Centre (Z), Module (M), Focus (S)

■[N] Breast cancer centre recognised after NRW certification (no DKG certificate)

■[M] Module Stomach / Liver

□ Transfer / transit (T)

113 locations

Status: 01.03.2017

Regional distribution of Oncology Centres and Comprehensive Cancer Centres



Legend

- Locations with a Comprehensive Cancer Centre and an Oncology Centre (certified and in ongoing certification process)
- Locations with a Comprehensive Cancer Centre
- Locations with an Oncology Centre

Radius:

30 km 15 km

DKG
KREBSGESELLSCHAFT

3.3 Certcalculator evaluations

Every year certified Oncology Centres must present their scale of care in what is called a "Certcalculator" in which the primary cases of tumour entities are listed which come under the Centre's scope.

The following evaluations take into account 113 locations which have a valid certificate as an Oncology Centre up to 01.03.2017.

Area of application

The scope of the Oncology Centres encompasses tumour entities which are evaluated during the audit. Oncology Centres must provide evidence of scope which comprises at least 50% of malignant tumours. In multi-location structures the scope of the individual locations may be added together.

As 7 of the locations which fall below the required value of 50% in the chart below are multi-location structures, this criterion is met by all Oncology Centres



Basis for the calculation:

Scope = Z + M + S + T ≥ 50%

M = Location of a multi-location centre
E = Individual location (centre with only one location)

In the case of multi-location centres, designated with "M" in the diagram, the 50% quota may be achieved by adding together the individual locations..

Area of application within the scale of care

The scope of coverage of at least 70% is met by all locations..



Basis for the calculation:

Scope in the scale of care
(applies to each individual location)
M = Location of a multi-location centre
E = Individual location (centre with only one location)

$$= \frac{Z + M + S + T}{Z + M + S + T + V} \geq 70\ \%$$

In the case of multi-location centres, designated with "M" in the diagram, the 70% quota must be achieved by each individual location.

Certcalculator – Distribution of evidence levels

Each individual location of an Oncology Centre presents its scope in the Certcalculator. For the following representation the Certcalculators from the 2016 audit year were evaluated

	Number of locations with evidence level [1]						**Evidence level Z, M, S**		**Evidence level T**	
	Z	**M**	**S**	**T**	**V**	**n**	Primary cases total	Primary cases median	Primary cases total	Primary cases median
Breast	97	---	---	3	3	10	21.710	194	228	74
Colon/rectum	106	---	---	6	---	1	10.093	93	271	43,5
Prostate	63	---	---	14	13	23	14.356	163	1.373	82
Lung	23	---	---	8	68	14	8.494	333	1530	198
Gynaecological tumours	68	---	---	14	21	10	7.306	87	799	50,5
Skin	40	---	---	4	14	55	34.504	671,5	1.116	294,5
Head and neck tumours	---	47	---	3	21	42	6.429	121	299	70
Neuro-oncological tumours	---	30	---	1	34	48	6.427	202,5	238	238
Pancreas	---	57	---	12	41	3	2.939	47	344	27
Stomach	---	14	83	---	15	1	2.866	25	---	---
Liver	---	13	55	---	33	12	1.931	15	---	---
Bladder	---	---	52	---	40	21	4.377	84	---	---
Kidney	---	---	56	---	37	20	3.263	46	---	---
Testicles, penis	---	---	46	---	44	23	866	18	---	---
Other gastrointestinal tumours	---	---	68	---	41	4	1.998	21,5	---	---
Oesophagus	---	---	76	---	30	7	1.585	17	---	---
Lymphoma	---	---	80	---	27	6	5.109	53	---	---
Leukaemia	---	---	69	---	30	14	2.785	31	---	---
Haematological syst. diseases	---	---	70	---	30	13	2.169	23	---	---
Endocrine malignomas	---	---	34	---	62	17	1.237	25,5	---	---
Musculoskeletal tumours	---	---	20	---	56	37	1.286	43	---	---

1) Evidence levels:

Z ... Organ Cancer Centre
M ... Module
S ... Focus
T ... Transfer / transit centre
V ... Active treatment but certification not considered within scope
n ... No treatment of this tumour entity

Individual evaluation of organ level

Breast





Evidence levels	Locations						Primary cases median					
	2010	2011	2012	2013	2014	2015	2010	2011	2012	2013	2014	2015
Z = Organ Cancer Centre	36	41	49	65	77	97	211	223	220	209	204	194
T = Transfer/transit centre	1	1	3	2	1	3	51	62	93	61	106	74
V = active treatment; not certified	3	2	2	2	5	3						
n = no treatment	4	7	6	11	11	10						
Total	44	51	60	80	94	113						

Colon/rectum





Evidence levels	Locations						Primary cases median					
	2010	2011	2012	2013	2014	2015	2010	2011	2012	2013	2014	2015
Z = Organ Cancer Centre	39	46	56	75	87	106	105	102	97	98	90	93
T = Transfer/transit centre	4	5	4	4	6	6	80	45	46	54	42	43,5
V = active treatment; not certified	1	0	0	0	0	0						
n = no treatment	0	0	0	1	1	1						
Total	44	51	60	80	94	113						

Prostate





Evidence levels	Locations						Primary cases median					
	2010	2011	2012	2013	2014	2015	2010	2011	2012	2013	2014	2015
Z = Organ Cancer Centre	20	25	31	40	47	63	224	195	153	153	146	163
T = Transfer/transit centre	10	9	8	9	14	14	90	108	100,5	93	79	82
V = active treatment; not certified	3	5	10	11	10	13						
n = no treatment	7	12	11	20	23	23						
Total	40	51	60	80	94	113						

Lung





Evidence levels	Locations						Primary cases median					
	2010	2011	2012	2013	2014	2015	2010	2011	2012	2013	2014	2015
Z = Organ Cancer Centre	7	9	11	16	18	23	270	310	332	304	299	333
T = Transfer/transit centre	16	15	10	8	9	8	76,5	97	186,5	174	186	198
V = active treatment; not certified	9	19	31	41	53	68						
n = no treatment	3	8	8	15	14	14						
Total	35	51	60	80	94	113						

Gynaecological tumours (cervix, uterus, ovaries including BOT, vulva, vaginal tumours)





Evidence levels	Locations						Primary cases median					
	2010	2011	2012	2013	2014	2015	2010	2011	2012	2013	2014	2015
Z = Organ Cancer Centre	15	17	32	44	52	68	92	105	85	85,5	102	87
T = Transfer/transit centre	14	20	14	11	17	14	39,5	51	47	47	44	50,5
V = active treatment; not certified	4	6	7	14	14	21						
n = no treatment	5	8	7	11	11	10						
Total	38	51	60	80	94	113						

Skin (melanoma, malignant epithelial tumours)





Evidence levels	Locations						Primary cases median					
	2010	2011	2012	2013	2014	2015	2010	2011	2012	2013	2014	2015
Z = Organ Cancer Centre	8	13	19	23	30	40	434	555	533	543	683	671,5
T = Transfer/transit centre	0	0	1	1	1	4	0	0	156	212	238	294,5
V = active treatment; not certified	5	8	8	13	17	14						
n = no treatment	14	30	32	43	46	55						
Total	27	51	60	80	94	113						

Head and neck tumours (mouth, pharynx, larynx)





Evidence levels	Locations						Primary cases median					
	2010	2011	2012	2013	2014	2015	2010	2011	2012	2013	2014	2015
M = Module	7	11	19	28	38	47	174	148	140	128	125,5	121
T = Transfer/transit centre	5	5	6	4	4	3	68	118	99,5	71,5	52	70
V = active treatment; not certified	8	15	14	17	14	21						
n = no treatment	7	20	21	31	38	42						
Total	27	51	60	80	94	113						

Neuro-oncological tumours





Evidence levels	Locations						Primary cases median					
	2010	2011	2012	2013	2014	2015	2010	2011	2012	2013	2014	2015
M = Module	2	7	10	18	22	30	567,5	172	168	167	197,5	202,5
T = Transfer/transit centre	5	2	7	3	5	1	72	73,5	101	107	117	238
V = active treatment; not certified	8	18	17	25	27	34						
n = no treatment	10	24	26	34	40	48						
Total	25	51	60	80	94	113						

Pancreas





Evidence levels	Locations						Primary cases median					
	2010	2011	2012	2013	2014	2015	2010	2011	2012	2013	2014	2015
M = Module	12	15	21	35	46	57	35	43	38	43	41	47
T = Transfer/transit centre	17	21	22	11	7	12	24,5	27	28	35	39	27
V = active treatment; not certified	6	13	16	30	37	41						
n = no treatment	1	2	1	4	4	3						
Total	36	51	60	80	94	113						

Stomach





Evidence levels	Locations						Primary cases median					
	2010	2011	2012	2013	2014	2015	2010	2011	2012	2013	2014	2015
M = Module	---	---	---	---	---	14	---	---	---	---	---	39
T = Transfer/transit centre	---	---	---	---	---	0	---	---	---	---	---	0
S = Focus	32	38	49	67	80	83	23,5	23	26	25	29	23
V = active treatment; not certified	4	12	11	12	13	15						
n = no treatment	0	1	0	1	1	1						
Total	36	51	60	80	94	113						

Liver





Evidence levels	Locations						Primary cases median					
	2010	2011	2012	2013	2014	2015	2010	2011	2012	2013	2014	2015
M = Module	---	---	---	---	---	13	---	---	---	---	---	68
T = Transfer/transit centre	---	---	---	---	---	0	---	---	---	---	---	0
S = Focus	---	---	---	---	---	55	---	---	---	---	---	13
V = active treatment; not certified	---	---	---	---	---	33						
n = no treatment	---	---	---	---	---	12						
Total	---	---	---	---	---	113						

Bladder (S6)





Evidence levels	Locations						Primary cases median					
	2010	2011	2012	2013	2014	2015	2010	2011	2012	2013	2014	2015
S = Focus	15	19	28	39	47	52	104	70	81,5	69	83	84
V = active treatment; not certified	5	20	21	22	27	40						
n = no treatment	8	12	11	19	20	21						
Total	28	51	60	80	94	113						

Kidney (S6)





Evidence levels	Locations						Primary cases median					
	2010	2011	2012	2013	2014	2015	2010	2011	2012	2013	2014	2015
S = Focus	18	23	31	45	52	56	52	50	53	53	51	46
V = active treatment; not certified	6	18	19	18	23	37						
n = no treatment	5	10	10	17	19	20						
Total	29	51	60	80	94	113						

Testicles, penis (S6)





Evidence levels	Locations						Primary cases median					
	2010	2011	2012	2013	2014	2015	2010	2011	2012	2013	2014	2015
S = Focus	13	15	24	35	41	46	18	19	12,5	16	15	18
V = active treatment; not certified	7	21	21	24	29	44						
n = no treatment	7	15	15	21	24	23						
Total	27	51	60	80	94	113						

Other gastrointestinal tumours (S1) (bile ducts, primary liver tumours, GIST, neuro-endocrine tumours)





Evidence levels	Locations						Primary cases median					
	2010	2011	2012	2013	2014	2015	2010	2011	2012	2013	2014	2015
S = Focus	10	17	27	45	60	68	23,5	23	26	36	40,5	21,5
V = active treatment; not certified	13	30	30	31	30	41						
n = no treatment	2	4	3	4	4	4						
Total	25	51	60	80	94	113						

Oesophagus (S1)





Evidence levels	Locations						Primary cases median					
	2010	2011	2012	2013	2014	2015	2010	2011	2012	2013	2014	2015
S = Focus	26	30	38	53	64	76	17	19,5	17,5	17	21	17
V = active treatment; not certified	6	17	19	21	24	30						
n = no treatment	0	4	3	6	6	7						
Total	32	51	60	80	94	113						

Lymphoma (S5)





Evidence levels	Locations						Primary cases median					
	2010	2011	2012	2013	2014	2015	2010	2011	2012	2013	2014	2015
S = Focus	26	34	44	56	68	80	34	41	52	54,4	53,3	53
V = active treatment; not certified	5	13	13	20	20	27						
n = no treatment	1	4	3	4	6	6						
Total	32	51	60	80	94	113						

Leukaemia (S5)





Evidence levels	Locations						Primary cases median					
	2010	2011	2012	2013	2014	2015	2010	2011	2012	2013	2014	2015
S = Focus	22	29	38	47	58	69	19	23	25,5	31	31	31
V = active treatment; not certified	7	15	15	21	23	30						
n = no treatment	1	7	7	12	13	14						
Total	30	51	60	80	94	113						

Haematological systemic diseases (S5) (plasmocytoma, inter alia)





Evidence levels	Locations						Primary cases median					
	2010	2011	2012	2013	2014	2015	2010	2011	2012	2013	2014	2015
S = Focus	15	25	38	48	59	70	20	21	23	22	21	23
V = active treatment; not certified	8	18	16	21	23	30						
n = no treatment	2	8	6	11	12	13						
Total	25	51	60	80	94	113						

Endocrine malignomas (S4) (including thyroid, neuroendocrine tumours, adrenal gland)



Evidence levels	Locations						Primary cases median					
	2010	2011	2012	2013	2014	2015	2010	2011	2012	2013	2014	2015
S = Focus	14	15	18	26	30	34	14,5	15	19,5	26,5	26,5	25,5
V = active treatment; not certified	11	26	29	39	48	62						
n = no treatment	3	10	13	15	16	17						
Total	28	51	60	80	94	113						

Musculoskeletal tumours (S2) (including soft tissue sarcomas)





Evidence levels	Locations						Primary cases median					
	2010	2011	2012	2013	2014	2015	2010	2011	2012	2013	2014	2015
S = Focus	7	7	9	10	16	20	18	40	38	46	38	43
V = active treatment; not certified	10	25	29	42	43	56						
n = no treatment	8	19	22	28	35	37						
Total	25	51	60	80	94	113						

DKG
KREBSGESELLSCHAFT

4. MEDIA / WEBPORTALS

oncoMAP

Since mid-2013 the certified centres have been presented in a user-friendly search engine on www.oncomap.de. Patients and other interested parties can now locate potential care facilities using individual search criteria like type of cancer and medical specialty and have them displayed in a map. The interdisciplinary treatment network can be viewed by simply clicking on each centre.

www.oncomap.de

studybox

All planned or ongoing studies in the certified centres are centrally listed and described in the StudyBox. The StudyBox informs centres, patients and their family members about current studies. The recording of studies for colorectal cancer centres started at the beginning of 2015Darmkrebsstudien im Deutschen Register Klinischer Studien (DRKS) und der StudyBox ist möglich.

The second step envisages an official recognition procedure for these studies according to criteria of the certification commission in the shape of accreditation. There are plans to extend the StudyBox to other organs at a later date.

Annual Report Organ Cancer Centres / Modules

Annual reports are published for the Organ Cancer Centres (breast, colorectal, gynaecological, skin, lung, prostate) and for the Modules (pancreas, head and neck, neuro-oncology). The purpose of these annual reports is to evaluate the key figures and quality indicators presented and verified in the certification process. Particularly important in this context is that the arguments of the centers for non-implementation of a quality indicator, the planned actions and the assessments of auditors are summarized and described. Based on these data, which do not draw on catalogues of requirements but on actual treated cases, recommendations for guidelines, interdisciplinary structures and the expertise of the main treatment partners, amongst other things, are depicted in the certified centres. These annual reports enable the centres to compare themselves with others and monitor their own development. At the same time, the scientific experts and the guideline groups receive important information about the care situation which is of importance for the ongoing development of medical standards

Download annual reports on www.krebsgesellschaft.de and www.onkozert.de.

XML OncoBox

Thanks to the XML-OncoBox it is possible to present the indicators and outcome quality in line with the certification requirements using XML technology. The precondition is that a tumour documentation system has the appropriate interface. At the present time there are functioning OncoBoxes for the breast, colorectal and prostate cancer.
Find out more on www.xml-oncobox.de/en

Innovations

Peadiatric Cancer Centre

DKG KREBSGESELLSCHAFT Certified Paediatric Cancer Centre

In 2016 the first pilot clinics for the new certification module „peadiatric cancer centre“ were successfully certified. As a module the pre-requisite for a certification is always the certified oncology centre. The new certification module will join in the regular certification process in the second part of 2017.

PCO-Study (PROM)

The globally active charity organization MOVEMBER started the study project “Prostate-Cancer-Outcomes” with the aim to improve the physical and psychological health of men suffering from a localized prostate carcinoma.

Clinics from different countries participate in this study. Goal of the study is to collect clinical data from the participating clinics as well as testimonials from patients about their pre- and post-treatment experiences of the localized prostate carcinoma (so called “patient reported outcomes – PROs”) and compare the data (anonymously).

Via a collective application from the German Cancer Society 23 certified prostate cancer centres located in Germany and Switzerland currently participate in the study.

Leading force for the initiation and implementation of the study is the Federal Association Prostate Cancer Self-Help e.V. (BPS) and the Society for Help for Prostate Cancer Patients e.V. (FHbP). OnkoZert is responsible for the technological infrastructure of the study (OncoBox Prostate, online survey portal).

Since the beginning of the study, 1 July 2016, within 6 month 1,201 patients have filled out the pre-therapeutic questionnaire.

www.pco-study.com

Information about the Certification System: www.krebsgesellschaft.de

In addition to further information about the certification system, it is now possible to download the minutes of certification commission meetings (http://www.krebsgesellschaft.de/deutsche-krebsgesellschaft-wtrl/deutschekrebsgesellschaft/zertifizierung/zentrumssuche/sitzungen-und-protokolle.html), the composition of certification commission (www.zertkomm.de) and publications of the certification system (https://www.krebsgesellschaft.de/deutsche-krebsgesellschaft-wtrl/ deutsche-krebsgesellschaft/publikationen/fachartikel.html) from the new website of the German Cancer Society.

References

[1] Ziele des Nationalen Krebsplans http://www.bmg.bund.de/fileadmin/dateien/Downloads/N/Nationaler_Krebsplan/Nationaler_Krebsplan-Zieluebersicht.pdf (21.01.2015).

[2] Wesselmann S, Benz S, Graeven U. Qualitätssicherung in der Onkologie-zertifizierte Netzwerke für Patienten. Zeitschrift für Allgemeinmedizin. 2014;90(11):464-8.

[3] Kowalski C, Ferencz J, Brucker SY, Kreienberg R, Wesselmann S. Quality of care in breast cancer centers: Results of benchmarking by the German Cancer Society and German Society for Breast Diseases. Breast. 2015:DOI: 10.1016/j.breast.2014.11.014. Wesselmann S, Winter A, Ferencz J, Seufferlein T, Post S. Documented quality of care in certified colorectal cancer centers in Germany: German Cancer Society benchmarking report for 2013. International Journal of Colorectal Disease. 2014;29(4):511-8.

[4] Wesselmann S, Beckmann MW, Winter A. The concept of the certification system of the German Cancer Society and its impact on gynecological cancer care. Archives of Gynecology and Obstetrics. 2014;289(1):7-12. Winter A, Iro H, Wolff KD, Wesselmann S. Certification of head and neck tumor centers by the German Cancer Society: an overview. HNO. 2013;61(11):914-20.

[5] Budewig K, Wesselmann S (2014) Die Krebsbekämpfung in der EU-Gesundheitspolitik und der Beitrag Deutschlands. Forum. DOI 10.1007/s12312-014-1169-0.

[6] Report on breast cancer in the European Union (2002/2279(INI)), Committee on Women's Rights and Equal Opportunities. A5–0159/2003 http://www.europarl.europa.eu/sides/getDoc.do?pubRef=-//EP//NONSGML+REPORT+A5–2003-0159+0+DOC+PDF+V0//EN.

[7] Sachverständigenrat für die Konzertierte Aktion im Gesundheitswesen. Bedarfsgerechtigkeit und Wirtschaftlichkeit, Band III Über-, Unter- und Fehlversorgung, Gutachten 2000/2001.

[8] Wesselmann S. (2013): Zertifizierungsmodelle der onkologischen Versorgung. Forum; doi:10.1007/s12312-013-0938-5.

[9] Research Data Centres of the Federal Statistical Office and the statistical offices of the Länder, hospital statistic 2009, 2012, individually calculation.

Authors

Deutsche Krebsgesellschaft e.V.
Certification Commission Oncology Centres
Ullrich Graeven, Speaker Certification Commission
Christoph von Kalle, Speaker Certification Commission
Hauke Lang, Speaker Certification Commission
Simone Wesselmann, Deutsche Krebsgesellschaft e.V.
Christoph Kowalski, Deutsche Krebsgesellschaft e.V.
Christian Odenwald, OnkoZert GmbH
Julia Ferencz, OnkoZert GmbH

ISBN: 978-3-946714-61-3

Imprint

Publisher and responsible for the content:
German Cancer Society (DKG)
Kuno-Fischer-Strasse 8
14057 Berlin
Germany
Tel.: +49 (030) 322 93 29 0
Fax: +49 (030) 322 93 29 66
Associations Register Charlottenburg Local Court,
Associations Register No.: VR 27661 B
Responsible according to press law:
Dr. Johannes Bruns

In co-operation with:
OnkoZert, Neu-Ulm
www.onkozert.de

Version A2; Status as of 23.01.2018



DKG
KREBSGESELLSCHAFT

FIRSTHAND KNOWLEDGE

Find out more on
www.krebsgesellschaft.de